← All Pds Biotechnology CORP filings

Pds Biotechnology CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PDSB
Pds Biotechnology CORP
10-K/A: PDS Biotechnology Corp. Files Annual Report Amendment
PDS Biotechnology Corporation has filed an amendment to its 2025 Annual Report on Form 10-K, primarily to include Part III disclosures regarding directors, executive officers, compensation, and related matters.
NASDAQ
PDSB
Pds Biotechnology CORP
10-K: PDS Biotech Advances Cancer Therapies, Reports Strong Trial Data
PDS Biotechnology Corporation's 2025 annual report highlights significant progress in its oncology pipeline with promising clinical trial results for PDS0101 and PDS01ADC, despite ongoing financial losses and a going concern warning.
NASDAQ
PDSB
Pds Biotechnology CORP
10-K: PDS Biotech Reports 2024 Results, Highlights Progress in Immunotherapy Pipeline
PDS Biotechnology Corporation files its 10-K report for the year ended December 31, 2024, detailing its financial results and progress in developing its Versamune and Infectimune immunotherapy platforms.
NASDAQ
PDSB
Pds Biotechnology CORP
10-K: PDS Biotechnology Corporation 10-K Filing: Immunotherapy Pipeline and Financial Overview
PDS Biotechnology Corporation's 10-K filing details its clinical-stage immunotherapy pipeline, financial status, and strategic direction for 2023.